Evidence map›Paper›PMID 42497865›Full record

ArticleCell reports. Medicine2026

Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment.

Tanvi Varadkar, Zhuoxin Zora Zhou, Yingnan Si, Jiashuai Zhang, Zhantao Du, Anjana Gautam Khanal, Srijita Chowdhury, Chandini Tsaliki, Lufang Zhou, Xiaoguang Margaret Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tanvi VaradkarDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Zhuoxin Zora ZhouDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Yingnan SiDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Jiashuai ZhangDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, USA.
Zhantao DuDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Anjana Gautam KhanalComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Srijita ChowdhuryDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Chandini TsalikiDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Lufang ZhouDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, USA; Department of Surgery, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Xiaoguang Margaret LiuDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Electronic address: liu.482@osu.edu.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Waters Select Series Cyclic IMS for P41 Native MS Resource Application to Alzheimer's DiseaseP41GM128577 · NIGMS · OHIO STATE UNIVERSITY · PI WYSOCKI, VICKI H. · 2018 to 2022
$7.6M
Native Mass Spectrometry Guided Structural Biology CenterRM1GM149374 · NIGMS · OHIO STATE UNIVERSITY · PI Vicki H. Wysocki · 2023 to 2026
$5.0M
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancerR01CA262028 · NCI · OHIO STATE UNIVERSITY · PI Xiaoguang Margaret Liu, Eddy Shih Hsin Yang · 2022 to 2026
$2.8M
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancersR01CA281980 · NCI · OHIO STATE UNIVERSITY · PI WILLIAM E. CARSON, Xiaoguang Margaret Liu · 2023 to 2026
$2.3M
Delineate the Pathophysiological Effect of Cardiomyocyte-specific Mitochondrial StressR01HL156581 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHOU, LUFANG · 2021 to 2025
$2.2M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA262028NCI NIH HHS R01 CA281980NHLBI NIH HHS R01 HL156581NIGMS NIH HHS P41 GM128577NIGMS NIH HHS RM1 GM149374
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive and chemotherapy-resistant subtype characterized by high metastatic potential and frequent recurrence, making monotherapies largely ineffective. This study evaluates a combination strategy utilizing a CD276 (B7-H3)-targeted antibody-drug conjugate (ADC) alongside mitochondria-targeted gene therapy. The anti-CD276 monoclonal antibody-mertansine conjugate substantially reduces tumor burden at a low dose. It exhibits strong synergy with the cmLumiOpto platform, enhancing cytotoxicity across three TNBC cell lines, impairing mitochondrial function, and elevating the tumoral immune response. Furthermore, the ADC/cmLumiOpto combination suppresses TNBC metastasis in mouse models and inhibits tumor growth by 95%-100% in patient-derived xenograft models. Mechanistic investigations reveal downregulated metastatic signaling, tumor microenvironment remodeling, increased apoptosis, and upregulated tumoral immunity. Histological and body weight analyses indicate minimal systemic toxicity. These findings highlight the translational potential of combining CD276-targeted ADC with mitochondrial gene therapy to treat aggressive TNBC.

Indexed as

ImmunoconjugatesMaytansineTriple Negative Breast NeoplasmsAnimalsApoptosisCell Line, TumorFemaleHumansMiceMitochondriaTumor MicroenvironmentXenograft Model Antitumor AssaysImmunoconjugatesMaytansineantibody-drug conjugateCD276 (B7-H3)combined therapymitochondria-targeted cmLumiOptotriple-negative breast cancer

Identifiers

PMID42497865
PMCPMC13522777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.